![A fully implantable device for diffuse insulin delivery at extraperitoneal site for physiological treatment of type 1 diabetes - ScienceDirect A fully implantable device for diffuse insulin delivery at extraperitoneal site for physiological treatment of type 1 diabetes - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0168365920300754-ga1.jpg)
A fully implantable device for diffuse insulin delivery at extraperitoneal site for physiological treatment of type 1 diabetes - ScienceDirect
![Current trend in drug delivery considerations for subcutaneous insulin depots to treat diabetes - ScienceDirect Current trend in drug delivery considerations for subcutaneous insulin depots to treat diabetes - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0927776517300899-gr1.jpg)
Current trend in drug delivery considerations for subcutaneous insulin depots to treat diabetes - ScienceDirect
InsuLife AS to acquire insulin delivery technology, aiming to eliminate injections for millions of diabetics worldwide - InsuLife
![Current trend in drug delivery considerations for subcutaneous insulin depots to treat diabetes - ScienceDirect Current trend in drug delivery considerations for subcutaneous insulin depots to treat diabetes - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0927776517300899-gr3.jpg)
Current trend in drug delivery considerations for subcutaneous insulin depots to treat diabetes - ScienceDirect
InsuLife AS to acquire insulin delivery technology, aiming to eliminate injections for millions of diabetics worldwide - InsuLife
![Long‐Lasting Designer Insulin with Glucose‐Dependent Solubility Markedly Reduces Risk of Hypoglycemia - Qiu - 2019 - Advanced Therapeutics - Wiley Online Library Long‐Lasting Designer Insulin with Glucose‐Dependent Solubility Markedly Reduces Risk of Hypoglycemia - Qiu - 2019 - Advanced Therapeutics - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/099ff44a-0871-4a4a-8c0c-a59a7022794e/adtp201900128-fig-0001-m.jpg)